Biosynthetic neoantigen displayed on bacteria derived vesicles elicit systemic antitumour immunity

Meng, F.; Li, Liyan; Zhang, Zhirang; Lin, Zhongda; Zhang, Jinxie; Song, Xiaomin; Xue, Teng; Xing, Chenyang; Liang, Xin; Zhang, Xudong

doi:10.1002/jev2.12289

Cited by 25 publications

(10 citation statements)

References 59 publications

(87 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MSCs exhibited CD105, CD73 positive and CD34, CD45 negative (Figure S1b, c) patterns and were observed microscopically in a long spindle-shaped and vortex-like arrangement (Figure S1a). To prepare MSC-EVs with high PD-L1 expression, we constructed MSC-PD-L1 by lentiviral transfection and puromycin screening according to our previous protocol. , Expression of PD-L1 on MSC was demonstrated by immunofluorescence and flow cytometry analysis (Figure S1d, e). We isolated and purified the extracellular vesicles according to a previous protocol and characterized the morphology of both MSC-EVs and MSC- EVs-PD-L1 by electron microscopy (TEM) imaging (Figure a).…”

Section: Resultsmentioning

confidence: 99%

PD-L1-Expressing Extracellular Vesicles for the Treatment of Pneumonia

Wu,

Wang,

Song

et al. 2023

ACS Biomater. Sci. Eng.

View full text Add to dashboard Cite

Acute respiratory distress syndrome (ARDS) is a severe lung condition with a high mortality rate and a lack of effective drug therapy. In this work, we developed mesenchymal stem cell (MSC)-derived extracellular vesicles with high PD-L1 expression (MSC-EVs-PD-L1) for treating lipopolysaccharide (LPS)-induced pneumonia by intratracheal administration. We found an upregulation of PD-1 expression in the inflammatory region of murine lungs; hence, MSC-EVs-PD-L1 exerted immunosuppressive effects via the PD-1/PD-L1 signaling pathway. Furthermore, we treated LPS-induced pneumonia mice by intratracheal administration, which enabled heavy drug accumulation in the lungs of mice and better therapeutic efficacy compared to systemic administration. Our results suggest that MSC-EVs-PD-L1 has the potential to provide a universal platform technology for the immunotherapy of pneumonia.

show abstract

Section: Resultsmentioning

confidence: 99%

PD-L1-Expressing Extracellular Vesicles for the Treatment of Pneumonia

Wu,

Wang,

Song

et al. 2023

ACS Biomater. Sci. Eng.

View full text Add to dashboard Cite

show abstract

“…Bacterial outer membrane vesicles have robust immune adjuvant effects and can elicit high level antitumor immunity. [ 52 ] Meanwhile, extracellular vesicles have the advantage of easy genetic engineering, which can improve tumor microenvironment by displaying PD‐1 to block PD‐L1 on tumor cells. [ 53 ] In this study, PLGA is selected as the carrier material.…”

Section: Discussionmentioning

confidence: 99%

Ultrasound Responsive Nanovaccine Armed with Engineered Cancer Cell Membrane and RNA to Prevent Foreseeable Metastasis

Sun

Zhou

et al. 2023

Advanced Science

View full text Add to dashboard Cite

Cancer vaccine has been considered as a promising immunotherapy by inducing specific anti‐tumor immune response. Rational vaccination at suitable time to efficiently present tumor associated antigen will boost tumor immunity and is badly needed. Here, a poly (lactic‐co‐glycolic acid) (PLGA)‐based cancer vaccine of nanoscale is designed, in which engineered tumor cell membrane proteins, mRNAs, and sonosensitizer chlorin e6 (Ce6) are encapsulated at high efficiency. The nanosized vaccine can be efficiently delivered into antigen presentation cells (APCs) in lymph nodes after subcutaneous injection. In the APCs, the encapsulated cell membrane and RNA from engineered cells, which have disturbed splicing resembling the metastatic cells, provide neoantigens of metastatic cancer in advance. Moreover, the sonosensitizer Ce6 together with ultrasound irradiation promotes mRNA escape from endosome, and augments antigen presentation. Through 4T1 syngeneic mouse model, it has been proved that the proposed nanovaccine is efficient to elicit antitumor immunity and thus prevent cancer metastasis.

show abstract

“…Taken together, personalized cancer vaccines show great potential in cancer immunotherapy by inducing an effective and durable antitumor response. [ 118 ]…”

Section: Cancer Vaccines Loaded With Part Of Whole Tumor Antigensmentioning

confidence: 99%

Rethinking Antigen Source: Cancer Vaccines Based on Whole Tumor Cell/tissue Lysate or Whole Tumor Cell

Diao

Liu

2023

Advanced Science

View full text Add to dashboard Cite

Cancer immunotherapies have improved human health, and one among the important technologies for cancer immunotherapy is cancer vaccine. Antigens are the most important components in cancer vaccines. Generally, antigens in cancer vaccines can be divided into two categories: pre-defined antigens and unidentified antigens. Although, cancer vaccines loaded with predefined antigens are commonly used, cancer vaccine loaded with mixed unidentified antigens, especially whole cancer cells or cancer cell lysates, is a very promising approach, and such vaccine can obviate some limitations in cancer vaccines. Their advantages include, but are not limited to, the inclusion of pan-spectra (all or most kinds of ) antigens, inducing pan-clones specific T cells, and overcoming the heterogeneity of cancer cells. In this review, the recent advances in cancer vaccines based on whole-tumor antigens, either based on whole cancer cells or whole cancer cell lysates, are summarized. In terms of whole cancer cell lysates, the focus is on applying whole water-soluble cell lysates as antigens. Recently, utilizing the whole cancer cell lysates as antigens in cancer vaccines has become feasible. Considering that pre-determined antigen-based cancer vaccines (mainly peptide-based or mRNA-based) have various limitations, developing cancer vaccines based on whole-tumor antigens is a promising alternative.

show abstract

Biosynthetic neoantigen displayed on bacteria derived vesicles elicit systemic antitumour immunity

Cited by 25 publications

References 59 publications

PD-L1-Expressing Extracellular Vesicles for the Treatment of Pneumonia

PD-L1-Expressing Extracellular Vesicles for the Treatment of Pneumonia

Ultrasound Responsive Nanovaccine Armed with Engineered Cancer Cell Membrane and RNA to Prevent Foreseeable Metastasis

Rethinking Antigen Source: Cancer Vaccines Based on Whole Tumor Cell/tissue Lysate or Whole Tumor Cell

Contact Info

Product

Resources

About